scispace - formally typeset
F

Frank M. Sacks

Researcher at Harvard University

Publications -  520
Citations -  86842

Frank M. Sacks is an academic researcher from Harvard University. The author has contributed to research in topics: Cholesterol & Weight loss. The author has an hindex of 120, co-authored 490 publications receiving 80422 citations. Previous affiliations of Frank M. Sacks include Erasmus University Rotterdam & University of Texas Health Science Center at Houston.

Papers
More filters
Patent

Quantification of lipoproteins

TL;DR: In this article, the authors provide protocols and reagents for quantification of lipoproteins and lipoprotein particle populations comprising specific combinations of non-integral apolipoprotein proteins and integral apoprotein proteins, which is useful for the detection of diseases such as cardiovascular disease and an assessment of the risk of an individual to develop a disease.
Journal ArticleDOI

Five-year plan for nutrition research and training: Executive summary

TL;DR: A multidisciplinary panel of noted investigators from the ranks of active scientists outside the Institute to describe the state of nutrition science in the relevant areas and to identify promising research questions are described.
Journal ArticleDOI

A trilogy of primary prevention statin trials. Panel discussion.

TL;DR: Several suggestions were put forth to explain how the low dose used in MEGA elicited similar LDL-C reductions to those observed in WOSCOPS and AFCAPS/TexCAPS at higher doses including the body size hypothesis, genetic variation, and statin-diet interaction.
Journal ArticleDOI

Changes in bile acid subtypes and long-term successful weight-loss in response to weight-loss diets: The POUNDS lost trial.

TL;DR: In this article, the authors examined how changes in circulating BA subtypes induced by weight-loss diets were associated with improvements in adiposity, regional fat deposition and energy metabolism among overweight and obese adults.
Journal ArticleDOI

Lessons learned from the prospective pravastatin pooling project.

TL;DR: Pravastatin was shown to safely reduce all-cause mortality, fatal and nonfatal coronary events, and stroke events in patients with a broad range of patient characteristics.